HDAC2-dependent Antipsychotic-like Effects of Chronic Treatment with the HDAC Inhibitor SAHA in Mice

[1]  R. Palmiter,et al.  Detecting and Avoiding Problems When Using the Cre-lox System. , 2018, Trends in genetics : TIG.

[2]  F. Tarazi,et al.  Pimavanserin: novel pharmacotherapy for Parkinson’s disease psychosis , 2018, Expert opinion on drug discovery.

[3]  Yongchao Ge,et al.  Antipsychotic-induced Hdac2 transcription via NF-κB leads to synaptic and cognitive side effects , 2017, Nature Neuroscience.

[4]  Peter B. Jones,et al.  Lifetime antipsychotic medication and cognitive performance in schizophrenia at age 43 years in a general population birth cohort , 2017, Psychiatry Research.

[5]  L. DeLisi,et al.  Issues related to sex differences in antipsychotic treatment , 2016, Current opinion in psychiatry.

[6]  Giulio Genovese,et al.  Schizophrenia risk from complex variation of complement component 4 , 2016, Nature.

[7]  A. Guidotti,et al.  Behavioral and molecular neuroepigenetic alterations in prenatally stressed mice: relevance for the study of chromatin remodeling properties of antipsychotic drugs , 2016, Translational psychiatry.

[8]  J. González-Maeso,et al.  Epigenetic signaling in schizophrenia. , 2015, Cellular signalling.

[9]  P. Fletcher,et al.  Antipsychotics and Amotivation , 2015, Neuropsychopharmacology.

[10]  S. Leucht,et al.  Second‐generation antipsychotic effect on cognition in patients with schizophrenia—a meta‐analysis of randomized clinical trials , 2015, Acta psychiatrica Scandinavica.

[11]  C. Spencer,et al.  Biological Insights From 108 Schizophrenia-Associated Genetic Loci , 2014, Nature.

[12]  S. Siegel,et al.  Animal Models of Psychosis: Current State and Future Directions , 2014, Current Behavioral Neuroscience Reports.

[13]  Eric S. Lander,et al.  A polygenic burden of rare disruptive mutations in schizophrenia , 2014, Nature.

[14]  E. Banks,et al.  De novo mutations in schizophrenia implicate synaptic networks , 2014, Nature.

[15]  Adam W. Bero,et al.  Epigenetic Priming of Memory Updating during Reconsolidation to Attenuate Remote Fear Memories , 2014, Cell.

[16]  J. González-Maeso,et al.  Preclinical models of antipsychotic drug action. , 2013, The international journal of neuropsychopharmacology.

[17]  E. Nestler,et al.  Repressive Epigenetic Changes at the mGlu2 Promoter in Frontal Cortex of 5-HT2A Knockout Mice , 2013, Molecular Pharmacology.

[18]  T. Hensch,et al.  Perineuronal nets protect fast-spiking interneurons against oxidative stress , 2013, Proceedings of the National Academy of Sciences.

[19]  L. Monteggia,et al.  Loss of Histone Deacetylase 2 Improves Working Memory and Accelerates Extinction Learning , 2013, The Journal of Neuroscience.

[20]  H. Meltzer.  Update on typical and atypical antipsychotic drugs. , 2013, Annual review of medicine.

[21]  J. González-Maeso,et al.  Animal models of serotonergic psychedelics. , 2013, ACS chemical neuroscience.

[22]  L. Tsai,et al.  The potential of HDAC inhibitors as cognitive enhancers. , 2013, Annual review of pharmacology and toxicology.

[23]  Terrell Holloway,et al.  HDAC2 as a new target to improve schizophrenia treatment , 2013, Expert review of neurotherapeutics.

[24]  S. Miyamoto,et al.  Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents , 2012, Molecular Psychiatry.

[25]  S. Sealfon,et al.  Persistent effects of chronic clozapine on the cellular and behavioral responses to LSD in mice , 2012, Psychopharmacology.

[26]  Scott J. Russo,et al.  HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity , 2012, Nature Neuroscience.

[27]  C. Tamminga,et al.  Treating impaired cognition in schizophrenia. , 2012, Current pharmaceutical biotechnology.

[28]  E. Rolls,et al.  Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy , 2012, Nature Reviews Drug Discovery.

[29]  S. Haggarty,et al.  An epigenetic blockade of cognitive functions in the neurodegenerating brain , 2012, Nature.

[30]  W. Bobo,et al.  A 12-month randomized, open-label study of the metabolic effects of olanzapine and risperidone in psychotic patients: influence of valproic acid augmentation. , 2011, The Journal of clinical psychiatry.

[31]  T. Robbins,et al.  Animal models of neuropsychiatric disorders. , 2011, Annual review of clinical psychology.

[32]  H. Jockusch,et al.  Tumor Necrosis Factor-α (TNF-α) Regulates Shedding of TNF-α Receptor 1 by the Metalloprotease-Disintegrin ADAM8: Evidence for a Protease-Regulated Feedback Loop in Neuroprotection , 2010, The Journal of Neuroscience.

[33]  Todd H. Stokes,et al.  The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models , 2010, Nature Biotechnology.

[34]  Courtney A Miller,et al.  Inhibitors of Class 1 Histone Deacetylases Reverse Contextual Memory Deficits in a Mouse Model of Alzheimer's Disease , 2010, Neuropsychopharmacology.

[35]  M. Fukata,et al.  Protein palmitoylation in neuronal development and synaptic plasticity , 2010, Nature Reviews Neuroscience.

[36]  H. Kashima,et al.  Augmentation of atypical antipsychotics with valproic acid. An open‐label study for most difficult patients with schizophrenia , 2009, Human psychopharmacology.

[37]  N. Belyaev,et al.  Sodium valproate: an old drug with new roles. , 2009, Trends in pharmacological sciences.

[38]  Emma Y. Wu,et al.  Antidepressant Actions of Histone Deacetylase Inhibitors , 2009, The Journal of Neuroscience.

[39]  J. Os,et al.  Schizophrenia , 2009, The Lancet.

[40]  T. Boeckers,et al.  ProSAPiP2, a novel postsynaptic density protein that interacts with ProSAP2/Shank3. , 2009, Biochemical and biophysical research communications.

[41]  Brian E. Howard,et al.  Unsupervised assessment of microarray data quality using a Gaussian mixture model , 2009, BMC Bioinformatics.

[42]  S. Haggarty,et al.  HDAC2 negatively regulates memory formation and synaptic plasticity , 2009, Nature.

[43]  C. Tamminga,et al.  Divalproex ER Combined with Olanzapine or Risperidone for Treatment of Acute Exacerbations of Schizophrenia , 2009, Neuropsychopharmacology.

[44]  J. Delgado-García,et al.  Histone deacetylase inhibitors improve learning consolidation in young and in KA-induced-neurodegeneration and SAMP-8-mutant mice , 2008, Molecular and Cellular Neuroscience.

[45]  Donard S Dwyer,et al.  Antipsychotic Drugs: Comparison in Animal Models of Efficacy, Neurotransmitter Regulation, and Neuroprotection , 2008, Pharmacological Reviews.

[46]  M. Murphy,et al.  Schizophrenia therapy: beyond atypical antipsychotics , 2008, Nature Reviews Drug Discovery.

[47]  D. Gruol,et al.  Chronic CXCL10 alters the level of activated ERK1/2 and transcriptional factors CREB and NF-κB in hippocampal neuronal cell culture , 2008, Journal of Neuroimmunology.

[48]  T. Abel,et al.  Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. , 2008, Current opinion in pharmacology.

[49]  K. Lattal,et al.  Systemic or intrahippocampal delivery of histone deacetylase inhibitors facilitates fear extinction. , 2007, Behavioral neuroscience.

[50]  Xiaoxia Qi,et al.  Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. , 2007, Genes & development.

[51]  K. Rajewsky,et al.  Vagaries of conditional gene targeting , 2007, Nature Immunology.

[52]  D. Ruan,et al.  The different roles of cyclinD1-CDK4 in STP and mGluR-LTD during the postnatal development in mice hippocampus area CA1 , 2007, BMC Developmental Biology.

[53]  Li-Huei Tsai,et al.  Recovery of learning and memory is associated with chromatin remodelling , 2007, Nature.

[54]  Stuart C. Sealfon,et al.  Hallucinogens Recruit Specific Cortical 5-HT2A Receptor-Mediated Signaling Pathways to Affect Behavior , 2007, Neuron.

[55]  Maqc Consortium.  The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements , 2006, Nature Biotechnology.

[56]  J. John Mann,et al.  Cortical 5-HT2A Receptor Signaling Modulates Anxiety-Like Behaviors in Mice , 2006, Science.

[57]  B. Kinon,et al.  Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs , 2005, BMC medicine.

[58]  J. Lieberman,et al.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. , 2005, The New England journal of medicine.

[59]  R. Hughes.  The value of spontaneous alternation behavior (SAB) as a test of retention in pharmacological investigations of memory , 2004, Neuroscience & Biobehavioral Reviews.

[60]  L. Kochan,et al.  Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone. , 2004, Psychiatric services.

[61]  S. Sealfon,et al.  Transcriptome Fingerprints Distinguish Hallucinogenic and Nonhallucinogenic 5-Hydroxytryptamine 2A Receptor Agonist Effects in Mouse Somatosensory Cortex , 2003, The Journal of Neuroscience.

[62]  S. Kapur,et al.  Delayed onset hypothesis of antipsychotic action — a hypothesis tested and rejected , 2003, Schizophrenia Research.

[63]  A I Saeed,et al.  TM4: a free, open-source system for microarray data management and analysis. , 2003, BioTechniques.

[64]  Akira Sawa,et al.  Schizophrenia: Diverse Approaches to a Complex Disease , 2002, Science.

[65]  L. San,et al.  Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. , 2001, The American journal of psychiatry.

[66]  Christine Brun,et al.  In silico prediction of protein-protein interactions in human macrophages , 2001, BMC Research Notes.

[67]  Peter R. Mouton,et al.  Comparative evaluation of synaptophysin-based methods for quantification of synapses , 1996, Journal of neurocytology.

[68]  T. Goldberg,et al.  The Effect of Clozapine on Cognition and Psychiatric Symptoms in Patients with Schizophrenia , 1993, British Journal of Psychiatry.

[69]  Maqc Consortium.  The MicroArray Quality Control ( MAQC )-II study of common practices for the development and validation of microarray-based predictive models , 2012 .

[70]  T. Bredy,et al.  The histone deacetylase inhibitor valproic acid enhances acquisition, extinction, and reconsolidation of conditioned fear. , 2008, Learning & memory.

[71]  R. Conley,et al.  Adjunct Divalproex or Lithium to Clozapine in Treatment-Resistant Schizophrenia , 2006, Psychiatric Quarterly.

[72]  D. Daniel,et al.  Effect of Divalproex Combined with Olanzapine or Risperidone in Patients with an Acute Exacerbation of Schizophrenia , 2003, Neuropsychopharmacology.